Merck & Co., Inc. news

   Watch this stock
Showing stories 1 - 10 of about 170   

Articles published

MRK 52.65 -0.33 (-0.62%)
price chart
Merck andamp; Co., Inc. Top-Selling Drug Put At Risk By FDA Warning
Merck & Co., Inc. (NYSE:MRK) has seen its overall sales drop since FY11 as it has faced increased generic as well as biosimilar competition for some of its best-selling drugs.
FDA warns of severe joint pain risk with DPP-4 diabetes drugs  Fox News
Jefferies Rating Update on Merck & Company, Inc. (NYSE:MRK)
Major Brokerage house, Jefferies maintains its ratings on Merck & Company, Inc. (NYSE:MRK). In the latest research report, Jefferies lowers the target price from $63 per share to $57 per share on the shares.
Value Stock to Watch: Merck & Company, Inc. (NYSE:MRK)  Enterprise Leader
Shares of Merck & Company, Inc. (NYSE:MRK) Sees Large Outflow of Money  Insider Trading Report
Active Stocks Roundup: Merck & Co., Inc (NYSE:MRK), FirstEnergy Corp (NYSE:FE ...
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection ...
FDA Approves Pediatric Indication for EMEND� (aprepitant) Capsules in ...  Benzinga
Merck : FDA approves sNDA for EMEND capsules - Quick facts  RTT News
Merck & Co. Inc. (MRK) Closes 0.86% Up on the Day for September 02
Merck & Co. Inc. currently has a total float of 2.82 billion shares and moves n/a a day, on average. The stock opened at $53.17 on September 02 and traded between a low of $52.35 and a high of $53.27.
Merck andamp; Co., Inc. (MRK) Stock Update
Pharmaceutical giant Merck & Co., Inc.'s (NYSE:MRK) stock has performed modestly well this year, with some steep increases to offset the few declines.
Merck & Co. Inc. (NYSE:MRK) Skyrockets on FDA Green Signal against ...  StreetWise Report
Merck & Co., Inc. (NYSE:MRK) announced that the FDA has accepted its ...
Merck & Co., Inc. (NYSE:MRK) announced that the FDA has accepted its supplemental Biologics License Application (sBLA) for Keytruda, an anti-PD-1 therapy, for review.
Why Merck andamp; Co., Inc. (MRK) Has Been Upgraded To An Outperform At BMO
Merck & Co., Inc. (NYSE:MRK) stock has been upgraded from a Market Perform to An Outperform at BMO Capital, by analysts Alex Arfaei and David Redfern via a report released August 13.
BMO Capital Markets Upgrades Merck & Co. Inc (NYSE:MRK) to " ...  OctaFinance.com
Good Data May Be Coming For Merck (And This Analyst Is Bullish)  Benzinga
Why Wayfair Inc. (W), Alibaba Group Holding Ltd (BABA) and Merck &Co., Inc ...
All told, crude oil gained more than 7%, while the S&P 500 Index lost 0.84% of its value. It was much worse for Merck & Co., Inc. (NYSE:MRK), Wayfair Inc. (NYSE:W) and Alibaba Group Holding Ltd (NYSE:BABA) shareholders, however. Here's why.
Worth Watching Stocks - Micron Technology, Inc. (NASDAQ:MU) Merck & Co. Inc ...
On Friday, Shares of Micron Technology, Inc. (NASDAQ:MU), gained 1.85% to $15.96, after the chairman of China's Tsinghua Unigroup came to the U.S.
Merck & Co Inc (NYSE:MRK) Declined on Trading Screens
[Business Wire] Merck & Co Inc (NYSE:MRK) (TREND ANALYSIS) asked that all customers, including patients, inspect all bottles of TEMODAR� (temozolomide) capsules and all bottles of Temozolomide capsules (generic) for potential cracks in the ...